2022
Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma.
Buza N, Hui P. Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma. Archives Of Pathology & Laboratory Medicine 2022, 146: 0. PMID: 35687792, DOI: 10.5858/arpa.2021-0547-oa.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaClinical trial criteriaHER2 gene amplificationTrial criteriaHER2 immunohistochemistrySerous carcinomaAnti-human epidermal growth factor receptor 2 (HER2) therapyClinical Oncology/CollegeHER2 testing algorithmHER2 FISHProspective clinical investigationHER2 IHC 2HER2/CEP17Gene amplificationContext of breastTherapeutic responseIHC 2HER2 amplificationAverage HER2Most tumorsClinical investigationImmunohistochemistryHER2 fluorescenceTumorsMonosomy 17
2014
T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo
English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi D, Azodi M, Schwartz PE, Rutherford TJ, Santin AD. T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. Cancer Medicine 2014, 3: 1256-1265. PMID: 24890382, PMCID: PMC4302675, DOI: 10.1002/cam4.274.Peer-Reviewed Original ResearchMeSH KeywordsAdo-Trastuzumab EmtansineAgedAged, 80 and overAnimalsAntibodies, Monoclonal, HumanizedAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsApoptosisCarcinomaCell Cycle CheckpointsCell ProliferationDisease Models, AnimalFemaleGene AmplificationGene ExpressionGene Expression Regulation, NeoplasticHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMaytansineMiddle AgedReceptor, ErbB-2RNA, MessengerTrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsUterine serous carcinomaUSC cell linesNovel antibody-drug conjugateT-DM1USC xenograftsAntibody-drug conjugatesSerous carcinomaAntibody-dependent cell-mediated cytotoxicityEpidermal growth factor receptor 2Cell linesPrimary USC cell linesGrowth factor receptor 2Cell-mediated cytotoxicityChromium release assaysNovel treatment optionsHER2 protein overexpressionFactor receptor 2HER2 gene amplificationHER2 protein expressionC-erbB2 gene amplificationGene amplificationDisease refractoryPrimary HER2USC cellsUSC patients
2013
Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma
Buza N, Hui P. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes And Cancer 2013, 52: 1178-1186. PMID: 24123408, DOI: 10.1002/gcc.22113.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaHER2/neu gene amplificationNeu gene amplificationSerous carcinomaHER2 protein expressionGene amplificationHeterogeneous tumorsProtein expressionHER2 testing guidelinesHER2 protein overexpressionTumor tissue areaTumor tissue sectionsHER2 statusDifferent tumor samplesHER2 overexpressionHER2 amplificationBreast cancerImmunohistochemical scoreAggressive subclonesCarcinomaClinical testingImmunostaining patternTumor samplesTumor cellsTesting guidelinesChromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification
Orsaria M, Khelifa S, Buza N, Kamath A, Hui P. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification. Journal Of Clinical Pathology 2013, 66: 1070. PMID: 23908451, DOI: 10.1136/jclinpath-2013-201506.Peer-Reviewed Original ResearchConceptsInvasive breast carcinomaHER2 protein overexpressionPolysomy 17Breast carcinomaHistological parametersPoor Nottingham Prognostic IndexGene amplificationPrimary invasive breast carcinomasLocal tumor extentProgesterone receptor negativityNottingham Prognostic IndexHigh histological gradeProtein overexpressionHigh nuclear gradeCEP17 copy numberChromosome 17 polysomyReceptor negativity